ID

34473

Beschrijving

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach; ODM derived from: https://clinicaltrials.gov/show/NCT01138527

Link

https://clinicaltrials.gov/show/NCT01138527

Trefwoorden

  1. 17-01-19 17-01-19 -
  2. 27-05-19 27-05-19 -
Houder van rechten

see on clinicaltrials.gov

Geüploaded op

17 januari 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Prostate Cancer NCT01138527

Eligibility Prostate Cancer NCT01138527

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
biopsy-proven diagnosis of adenocarcinoma of the prostate
Beschrijving

ID.1

Datatype

boolean

subject will sign a consent form prior to study entry
Beschrijving

ID.2

Datatype

boolean

radical prostatectomy and histopathological exam planned
Beschrijving

ID.3

Datatype

boolean

the time interval between last biopsy and the mr exam must be at least 4 weeks
Beschrijving

ID.4

Datatype

boolean

the time interval between mr exam and radical prostatectomy should not exceed 12 weeks
Beschrijving

ID.5

Datatype

boolean

Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects who are unable to give valid informed consent
Beschrijving

ID.6

Datatype

boolean

subjects who are unwilling or unable to undergo an mr exam, including subjects with contra-indications to mr exams
Beschrijving

ID.7

Datatype

boolean

therapy or surgical procedure applied to the prostate or to other organs in vicinity to the prostate: among the therapies preventing inclusion are any form of radiation therapy, cryo-therapy, thermal-therapy, therapy based on any other medication (including hormonal therapy).
Beschrijving

ID.8

Datatype

boolean

patients under hormone deprivation therapy.
Beschrijving

ID.9

Datatype

boolean

Similar models

Eligibility Prostate Cancer NCT01138527

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
biopsy-proven diagnosis of adenocarcinoma of the prostate
boolean
ID.2
Item
subject will sign a consent form prior to study entry
boolean
ID.3
Item
radical prostatectomy and histopathological exam planned
boolean
ID.4
Item
the time interval between last biopsy and the mr exam must be at least 4 weeks
boolean
ID.5
Item
the time interval between mr exam and radical prostatectomy should not exceed 12 weeks
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
subjects who are unable to give valid informed consent
boolean
ID.7
Item
subjects who are unwilling or unable to undergo an mr exam, including subjects with contra-indications to mr exams
boolean
ID.8
Item
therapy or surgical procedure applied to the prostate or to other organs in vicinity to the prostate: among the therapies preventing inclusion are any form of radiation therapy, cryo-therapy, thermal-therapy, therapy based on any other medication (including hormonal therapy).
boolean
ID.9
Item
patients under hormone deprivation therapy.
boolean

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial